Literature DB >> 24685608

Viral replication kinetics and in vitro cytopathogenicity of parental and reassortant strains of bluetongue virus serotype 1, 6 and 8.

Peter Coetzee1, Moritz Van Vuuren2, Maria Stokstad3, Mette Myrmel4, René G P van Gennip5, Piet A van Rijn6, Estelle H Venter7.   

Abstract

Bluetongue virus (BTV), a segmented dsRNA virus, is the causative agent of bluetongue (BT), an economically important viral haemorrhagic disease of ruminants. Bluetongue virus can exchange its genome segments in mammalian or insect cells that have been co-infected with more than one strain of the virus. This process, may potentially give rise to the generation of novel reassortant strains that may differ from parental strains in regards to their phenotypic characteristics. To investigate the potential effects of reassortment on the virus' phenotype, parental as well as reassortant strains of BTV serotype 1, 6, 8, that were derived from attenuated and wild type strains by reverse genetics, were studied in vitro for their virus replication kinetics and cytopathogenicity in mammalian (Vero) cell cultures. The results indicate that genetic reassortment can affect viral replication kinetics, the cytopathogenicity and extent/mechanism of cell death in infected cell cultures. In particular, some reassortants of non-virulent vaccine (BTV-1 and BTV-6) and virulent field origin (BTV-8) demonstrate more pronounced cytopathic effects compared to their parental strains. Some reassortant strains in addition replicated to high titres in vitro despite being composed of genome segments from slow and fast replicating parental strains. The latter result may have implications for the level of viraemia in the mammalian host and subsequent uptake and transmission of reassortant strains (and their genome segments) by Culicoides vectors. Increased rates of CPE induction could further suggest a higher virulence for reassortant strains in vivo. Overall, these findings raise questions in regards to the use of modified-live virus (MLV) vaccines and risk of reassortment in the field. To further address these questions, additional experimental infection studies using insects and/or animal models should be conducted, to determine whether these results have significant implications in vivo.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bluetongue; Bluetongue virus; Cytopathogenicity; Reassortment; Replication kinetics

Mesh:

Substances:

Year:  2014        PMID: 24685608     DOI: 10.1016/j.vetmic.2014.03.006

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.

Authors:  Sandra G P van de Water; René G P van Gennip; Christiaan A Potgieter; Isabel M Wright; Piet A van Rijn
Journal:  J Virol       Date:  2015-06-10       Impact factor: 5.103

2.  Emergence of a Novel Reassortant Strain of Bluetongue Serotype 6 in Israel, 2017: Clinical Manifestations of the Disease and Molecular Characterization.

Authors:  Natalia Golender; Avi Eldar; Marcelo Ehrlich; Yevgeny Khinich; Gabriel Kenigswald; Joseph Seffi Varsano; Shachar Ertracht; Itzik Abramovitz; Itay Assis; Ily Shlamovitz; Eitan Tiomkin; Erez Yonay; Benny Sharir; Velizar Y Bumbarov
Journal:  Viruses       Date:  2019-07-10       Impact factor: 5.048

3.  Proteomic analysis of sheep primary testicular cells infected with bluetongue virus.

Authors:  Junzheng Du; Shanshan Xing; Zhancheng Tian; Shandian Gao; Junren Xie; Huiyun Chang; Guangyuan Liu; Jianxun Luo; Hong Yin
Journal:  Proteomics       Date:  2016-04-13       Impact factor: 3.984

4.  Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV).

Authors:  Piet A van Rijn; Sandra G P van de Water; Femke Feenstra; René G P van Gennip
Journal:  Virol J       Date:  2016-07-02       Impact factor: 4.099

5.  Assessment of cross-protection induced by a bluetongue virus (BTV) serotype 8 vaccine towards other BTV serotypes in experimental conditions.

Authors:  Ludovic Martinelle; Fabiana Dal Pozzo; Christine Thys; Ilse De Leeuw; Willem Van Campe; Kris De Clercq; Etienne Thiry; Claude Saegerman
Journal:  Vet Res       Date:  2018-07-16       Impact factor: 3.683

6.  Bluetongue Serotype 3 in Israel 2013-2018: Clinical Manifestations of the Disease and Molecular Characterization of Israeli Strains.

Authors:  Natalia Golender; Velizar Bumbarov; Avi Eldar; Alessio Lorusso; Gabriel Kenigswald; Joseph Seffi Varsano; Dan David; Shani Schainin; Ilan Dagoni; Iosef Gur; Alon Kaplan; Anna Gorohov; Ori Koren; Eldad Oron; Yevgeny Khinich; Ily Sclamovich; Abraham Meir; Giovanni Savini
Journal:  Front Vet Sci       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.